Looks like you’re on a mobile device. The Cancer Immunity Cycle Experience is only available for desktop users. Please visit us again on a computer.
View and download a wealth of educational resources for personal use
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; ASH: American Society of Hematology; BiTE: Bispecific T-cell Engager; CLDN18.2: claudin-18 isoform 2; DLL3: delta-like protein 3; FGFR2b: fibroblast growth factor receptor 2 isoform lllb; FN: febrile neutropenia; G-CSF: Granulocyte-colony stimulating factor; ICR: International Consensus Report; ITP: Immune thrombocytopenia; KRAS: Kirsten rat sarcoma; MCL-1: myeloid cell leukemia-1; mCRC: metastatic colorectal cancer; mCRPC: metastatic castration-resistant prostate cancer; MOA: mechanism of action; MRD: minimal residual disease; MUC17: mucin 17; NSCLC: non-small cell lung cancer; PSMA: prostate-specific membrane antigen; SCLC: small cell lung cancer; SREs: skeletal-related events; STEAP1: six-transmembrane epithelial antigen of prostate 1; TPO: thrombopoietin.